Denali Therapeutics Inc.

NasdaqGS:DNLI 株式レポート

時価総額：US$3.0b

Denali Therapeutics マネジメント

マネジメント 基準チェック /44

Denali Therapeuticsの CEO はRyan Wattsで、 Aug2015年に任命され、 の在任期間は 10.75年です。 の年間総報酬は$ 4.75Mで、 15.1%給与と84.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.43%を直接所有しており、その価値は$ 42.21M 。経営陣と取締役会の平均在任期間はそれぞれ7.3年と7.1年です。

主要情報

Ryan Watts

最高経営責任者

US$4.8m

報酬総額

CEO給与比率15.11%
CEO在任期間10.8yrs
CEOの所有権1.4%
経営陣の平均在職期間7.3yrs
取締役会の平均在任期間7.1yrs

経営陣の近況

Recent updates

Seeking Alpha • May 03

Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform

Summary Denali Therapeutics has transitioned from a speculative platform to a commercial-stage rare disease company with FDA approval of AVLAYAH for Hunter syndrome. DNLI’s TransportVehicle technology enables delivery of biologics across the blood-brain barrier, providing significant differentiation and commercial potential in neurodegenerative and lysosomal storage diseases. With $1.17 billion in pro-forma liquidity and a focused initial launch, DNLI is positioned for 2.8 years of runway, reducing near-term capital risk. While valuation appears high on sales multiples, DNLI’s now-validated platform and pipeline optionality make the current price/book premium reasonable for early-stage commercial growth. Read the full article on Seeking Alpha
分析記事 • May 08

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Mar 20

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead

Summary Denali Therapeutics' stock has significantly dropped from $100 to $15 since 2021, but the company is now heavily derisked with promising product candidates nearing key milestones. Lead asset DNL310 shows strong biomarker data for Hunter syndrome, with plans for a BLA submission and accelerated approval by Q2 2025. The Biogen partnership for Parkinson’s Disease asset DNL151 includes substantial milestone payments and profit-sharing, highlighting its potential impact. Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock prices. Read the full article on Seeking Alpha
Seeking Alpha • Jan 09

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains

Summary Denali Therapeutics Inc.'s DNL343 failed to meet the primary endpoint in the phase 2/3 HEALY ALS trial, but potential biomarker analyses in 2025 may offer a path forward. Despite the trial setback in ALS, Denali's stock remains stable due to continued pre-specified analyses expected in late 2025. BLA filing of tividenofusp alfa for the treatment of patients with MPS II remains on track under the Accelerated Approval Pathway Program in early 2025. Financially, Denali has $1.28 billion in cash but may need additional funding in 2025, posing a risk of shareholder dilution. Read the full article on Seeking Alpha
分析記事 • Dec 09

We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Aug 20

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Summary Denali Therapeutics' proprietary Transport Vehicle technology enables drug delivery across the blood-brain barrier, targeting neurodegenerative diseases. DNL310, targeting MPS II, and DNL343 for ALS are key drug candidates with potential, though competition is significant. The company’s $500 million capital raise supports its aggressive R&D investment, providing a runway for developing its pipeline. Despite its promising platform, DNLI still has a relatively high cash burn and regulatory hurdles before achieving drug approval. Due to Denali's high-risk, long-term biotech development, I deem DNLI a DCA "buy" for investors who understand the inherent risks. Read the full article on Seeking Alpha
分析記事 • Jul 26

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
分析記事 • May 23

Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

Denali Therapeutics Inc. ( NASDAQ:DNLI ) shareholders would be excited to see that the share price has had a great...
Seeking Alpha • May 13

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

Summary Denali Therapeutics Inc.'s DNL-310 is currently being explored in an ongoing phase 2/3 COMPASS study for treatment of patients with MPS II; Enrollment completion expected in 2024. Denali is in talks with CDER division of FDA to seek for Accelerated Approval pathway for DNL-310 for the treatment of patients with MPS II. Biomarker and safety data from a phase 1/2 study, using DNL-126 for the treatment of patients with MPS IIIA, expected end of 2024. Another promising program from the pipeline is the development of DNL-343, which is being advanced in the phase 2/3 HEALEY ALS Platform trial for treatment of patients with amyotrophic lateral sclerosis. Read the full article on Seeking Alpha
分析記事 • Apr 17

An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Key Insights Using the 2 Stage Free Cash Flow to Equity, Denali Therapeutics fair value estimate is US$30.71 Denali...
分析記事 • Mar 21

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Those holding Denali Therapeutics Inc. ( NASDAQ:DNLI ) shares would be relieved that the share price has rebounded 25...
Seeking Alpha • Mar 07

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Summary Denali's stock performance has been flat despite the biotech sector's 20% rise; recently raised $500 million in a PIPE. ALS trial failure with partner Sanofi pressured stock; Denali's focus is on transport vehicle (TV) technology and BBB crossing. Denali boasts a strong financial position with $1.53 billion in cash, extending operational runway significantly. Recommends "buy" based on Denali's innovative TV technology, financial health, and potential in neurological disorders despite biotech risks. Read the full article on Seeking Alpha
分析記事 • Feb 21

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
分析記事 • Jan 26

Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

Denali Therapeutics Inc.'s ( NASDAQ:DNLI ) price-to-sales (or "P/S") ratio of 7x might make it look like a buy right...
分析記事 • Nov 20

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
分析記事 • Oct 09

Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

With a median price-to-sales (or "P/S") ratio of close to 10.4x in the Biotechs industry in the United States, you...
分析記事 • Aug 22

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

CEO報酬分析

Denali Therapeutics の収益と比較して、Ryan Watts の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

-US$508m

Dec 31 2025US$5mUS$718k

-US$513m

Sep 30 2025n/an/a

-US$499m

Jun 30 2025n/an/a

-US$479m

Mar 31 2025n/an/a

-US$454m

Dec 31 2024US$7mUS$690k

-US$423m

Sep 30 2024n/an/a

-US$427m

Jun 30 2024n/an/a

-US$420m

Mar 31 2024n/an/a

-US$137m

Dec 31 2023US$8mUS$670k

-US$145m

Sep 30 2023n/an/a

-US$124m

Jun 30 2023n/an/a

-US$128m

Mar 31 2023n/an/a

-US$371m

Dec 31 2022US$9mUS$645k

-US$326m

Sep 30 2022n/an/a

-US$303m

Jun 30 2022n/an/a

-US$284m

Mar 31 2022n/an/a

-US$286m

Dec 31 2021US$13mUS$610k

-US$291m

Sep 30 2021n/an/a

US$30m

Jun 30 2021n/an/a

US$56m

Mar 31 2021n/an/a

US$58m

Dec 31 2020US$9mUS$589k

US$71m

Sep 30 2020n/an/a

-US$228m

Jun 30 2020n/an/a

-US$216m

Mar 31 2020n/an/a

-US$215m

Dec 31 2019US$5mUS$567k

-US$198m

報酬と市場: Ryanの 総報酬 ($USD 4.75M ) は、 US市場 ($USD 7.02M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Ryanの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Ryan Watts (49 yo)

10.8yrs
在職期間
US$4,751,515
報酬

Dr. Ryan J. Watts, Ph D., serves as Director at PEEL Therapeutics, Inc. since February 2023. He is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since Au...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Ryan Watts
Co-Founder10.8yrsUS$4.75m1.43%
$ 42.2m
Alexander Schuth
Co-Founder11.2yrsUS$4.26m0.42%
$ 12.4m
Dana Andersen
Chief Technical and Manufacturing Officer7.8yrsデータなしデータなし
Joe Lewcock
Chief Scientific Officer5.8yrsデータなしデータなし
Chris Walsh
General Counsel7.3yrsデータなしデータなし
Cindy Dunkle
Chief People Officerno dataデータなしデータなし
Katie Peng
Chief Commercial Officer4.7yrsデータなしデータなし
Peter Chin
Acting Chief Medical Officer & Head of Developmentless than a yearデータなし0.13%
$ 3.8m
7.3yrs
平均在職期間
53yo
平均年齢

経験豊富な経営陣: DNLIの経営陣は経験豊富で経験豊富です（平均在職期間は7.3年）。

取締役

名称ポジション在職期間報酬所有権
Ryan Watts
Co-Founder11.2yrsUS$4.75m1.43%
$ 42.2m
Jay Flatley
Independent Director11.1yrsUS$316.38k0.22%
$ 6.5m
Julian Baker
Independent Chairpersonless than a yearUS$474.35k0.21%
$ 6.1m
Eric Reiman
Member of Scientific Advisory Boardno dataデータなしデータなし
David Schenkein
Independent Director11.1yrsUS$311.38k0.042%
$ 1.2m
David Holtzman
Member of Scientific Advisory Board5.5yrsデータなしデータなし
Peter Klein
Independent Director8.2yrsUS$318.88k0.014%
$ 400.6k
Jennifer Cook
Independent Director7.5yrsUS$301.38k0.013%
$ 373.6k
Steve Krognes
Independent Director4yrsUS$297.15k0.51%
$ 15.1m
Stacie Weninger
Member of Scientific Advisory Board5.3yrsデータなしデータなし
Henrik Zetterberg
Member of Scientific Advisory Board7.1yrsデータなしデータなし
Nancy Thornberry
Independent Director5.3yrsUS$306.38k0.012%
$ 348.2k
7.1yrs
平均在職期間
61yo
平均年齢

経験豊富なボード: DNLIの 取締役会 は 経験豊富 であると考えられます ( 7.1年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/24 14:48
終値2026/05/22 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Denali Therapeutics Inc. 19 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。31

アナリスト機関
null nullBaird
Joel BeattyBaird
Charles MooreBaird